Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vofatamab plus pembrolizumab in advanced or metastatic urothelial carcinoma
NL-OMON48991Phase 2Withdrawn
- Sponsor
- Rainier Therapeutics, Inc.
- Start
- Sep 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of vofatamab and pembrolizumab in transitional cell carcinoma (TCC) and bladder cancer (2 cohorts), sponsored by Rainier Therapeutics, Inc. Primary endpoints: Dose-limiting toxicities, Recommended phase 2 dose and 3 more. Planned start Sep 2017; status: withdrawn.
02
Drugs
vofatamabpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON48991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48991.